As part of our ongoing series focussing on new registrations in Australia, we have added a product review of the use of Budesonide orally disintegrating tablets for eosinophilic oesophagitis in adults.
This review discusses the disease burden, treatment options, mechanism of action, contraindications and some key studies focussed on the use of Budesonide.
Commentary is provided by Associate Professor Hamish Philpott, a staff specialist in the Northern Adelaide Local Health Network (NALHN – Modbury and Lyell McEwin Hospitals) and a Senior Clinical Lecturer at the University of Adelaide.
Please login below to download this issue (PDF)